Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232992 | 1.00 | KEAP1 (0.48) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| Potassium SCHEMBL1843363 | 0.98 | KEAP1 (0.47) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL21195978 | 0.84 | LMNA (0.41) | KEAP1NFE2L2ALDH1A1LMNACASP1 | |
| SCHEMBL31364654 | 0.84 | LMNA (0.41) | KEAP1NFE2L2ALDH1A1LMNACASP1 | |
| SCHEMBL24402344 | 0.82 | SMN1; SMN2 (0.41) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL535611 | 0.81 | KDM4E (0.47) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL535620 | 0.81 | KDM4E (0.39) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL31330687 | 0.81 | KDM4E (0.39) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL30495159 | 0.81 | KDM4E (0.39) | KEAP1NFE2L2KDM4ETDP1CYP3A4 | |
| SCHEMBL30067156 | 0.81 | KEAP1 (0.46) | KEAP1NFE2L2KDM4ETDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2025136936-A1 | AGONISTS OF TREM2 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| EP-4430029-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-8247431-B2 | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| EP-2144898-B1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2144898-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008130021-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130021-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | KEAP1 16/4885NFE2L2 61/4885KDM4E 1482/4885 |
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | KEAP1 784/4885NFE2L2 339/4885KDM4E 3817/4885 |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | KEAP1 751/4885NFE2L2 333/4885KDM4E 3909/4885 |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, CAT, DNPH1 | KEAP1 43/4885NFE2L2 698/4885KDM4E 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.